agilon health, inc. (AGL) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings report highlights declining membership, revenue, and medical margins, indicating operational and financial challenges. The Q&A session revealed uncertainties regarding Medicare policy, payer negotiations, and drug pricing. Despite some optimism for 2026, the lack of a share repurchase program and absence of clear guidance on key financial metrics further contribute to a negative sentiment. Given the company's small market cap, these factors are likely to result in a stock price decrease of 2% to 8% over the next two weeks.
Key Financial Performance
Membership 491,000 members in Q1 2025, down from 523,000 in Q1 2024, reflecting a slight year-over-year decline due to partner exits and a smaller 2025 class.
Total Revenue $1.53 billion in Q1 2025, compared to $1.60 billion in Q1 2024, a decrease driven by market and partnership exits, partially offset by premium growth.
Medical Margin $128 million in Q1 2025, down from $157 million in Q1 2024, primarily due to elevated utilization, flu-related costs, and negative prior period development.
Adjusted EBITDA $21 million in Q1 2025, compared to $29 million in Q1 2024, reflecting elevated cost trends offset by lower geography entry costs and operating cost initiatives.
Medical Cost Trend 5.5% in Q1 2025, compared to 6.7% in Q1 2024, with expectations for 2025 to run approximately 150 basis points lower than 2024.
Cash and Marketable Securities $369 million at the end of Q1 2025, with an additional $25 million off balance sheet cash held by ACO entities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Heart Failure Program: Recently launched heart failure program aimed at early identification and diagnosis of the disease via primary care doctors, supporting guideline-directed therapies to slow disease progression.
Palliative Program: Palliative program now live across most markets, focusing on improving quality of life for patients and reducing hospital admissions.
Medicare Advantage Membership: Membership at the end of Q1 2025 was 491,000, reflecting a slight decline due to partner exits and a smaller 2025 class.
Market Expansion: Continued focus on profitable growth in current markets and new geographies, with a disciplined approach to performance.
Cost Management: Maintaining cost discipline while investing in technology and clinical programs to support medical margin and patient outcomes.
Technology Investment: Investment in technology driving competitive advantage through improved automation, efficiency, and quality outcomes.
Payer Negotiations: Ongoing negotiations with payers to improve economic terms and predictability of performance, with approximately 50% of membership up for renewal on January 1, 2026.
Risk Reduction: Reduction in Medicare Part D exposure, with less than 30% of membership carrying Part D risk in 2025.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cost Trends: Continued elevated cost trends in medical expenses, particularly driven by inpatient admissions and Part B drug spend, which are impacting overall financial performance.
Membership Growth: Membership growth is cautious, with a flat year-over-year membership of 491,000, influenced by partner exits and a smaller 2025 class.
Regulatory Risks: Uncertainty surrounding future Medicare policy and potential changes in Medicare Advantage regulations, which could impact business operations.
Payer Negotiations: Ongoing negotiations with payers present risks related to economic terms and predictability of performance, especially with 50% of membership up for renewal in 2026.
Part D Exposure: Efforts to reduce exposure to Medicare Part D are ongoing, with less than 30% of membership carrying Part D risk, but this remains a significant area of concern.
Economic Factors: General economic pressures and market dynamics affecting the Medicare Advantage landscape, including competition and cost management challenges.
Operational Challenges: Need for continued investment in technology and clinical programs to enhance operational efficiency and manage costs effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Membership Growth Strategy: Agilon Health is taking a cautious approach to 2025 member growth, with a focus on a 3% growth rate in existing geographies and no underwriting risk.
Technology Investment: Investment in technology, including the acquisition of mphrX, is aimed at improving automation, efficiency, and clinical outcomes.
Clinical Pathways Program: The company is enhancing its clinical pathways program to improve early identification and management of chronic diseases.
Palliative Care Program: Expansion of the palliative care program is underway, focusing on improving quality of life for patients.
Cost Management Initiatives: Agilon is pursuing initiatives to reduce variability and improve performance, including better payer contracting and cost optimization.
Q2 2025 Membership Guidance: Expected Medicare Advantage membership in Q2 2025 is projected to be between 485,000 to 515,000.
Full Year 2025 Membership Guidance: Full year 2025 Medicare Advantage membership guidance remains unchanged at 490,000 to 520,000.
Q2 2025 Revenue Guidance: Expected revenue for Q2 2025 is between $1.44 billion to $1.51 billion.
Full Year 2025 Revenue Guidance: Full year 2025 revenue is expected to be in the range of $5.85 billion to $6.03 billion.
Q2 2025 Medical Margin Guidance: Medical margin for Q2 2025 is expected to be between $50 million and $70 million.
Full Year 2025 Medical Margin Guidance: Full year medical margins are projected to be between $275 million to $325 million.
Q2 2025 Adjusted EBITDA Guidance: Adjusted EBITDA for Q2 2025 is expected to be between negative $35 million to negative $20 million.
Full Year 2025 Adjusted EBITDA Guidance: Full year 2025 adjusted EBITDA guidance remains unchanged at negative $95 million to negative $55 million.
Cash Flow Expectations: Agilon expects to use approximately $110 million of cash in 2025, aiming for cash flow breakeven in 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give us a quick update on the company’s thinking around V-28, the impact specifically on 2025 and whether there’s anything different to consider relative to the impact you faced in 2024?
A:From a risk adjustment perspective in 2025, we’re in line with our expectations, 2% net increase year over year inclusive of about a 3% headwind from V-28. Our primary care physicians have continuity with their patients, and our membership in ’25 is essentially the same as in ’24.
Q:Can you talk about anything in terms of contribution from previously exited areas or other lingering impacts that you’re expecting for the rest of the year?
A:The $7 million unfavorable development for the exited markets will stay in 2024 and doesn’t impact 2025. We still have some IBNR left for those dates of service, but it’s minimal.
Q:Can you help us understand how the 2026 MA final rate notice will flow through agilon?
A:We repriced 40% of our membership for January 1 of '25, which will benefit from the average 9% increase across the network. We’re just starting the renewal process for 2026.
Q:Is the 2% pricing increase on a same patient basis?
A:Yes, the net 2% increase is on a same member basis, reflecting members we had last year.
Q:Can you talk about your expectation for the '26 MA bid cycle in terms of pricing benefits?
A:We’re optimistic about 2026, encouraged by the final rate notice and the bids submitted for 2025.
Q:Can you talk about the medical cost trend coming in higher than expected this quarter?
A:Medical cost trends were in line with our expectations, guided at plus 5%. We have better visibility now with our financial pipeline.
Q:What are your thoughts on drug pricing and the recent executive order?
A:We don’t believe we can materially manage Part D risk as most prescriptions are not written by our primary care physicians.
Q:Can you speak to the dynamics of the marketplace and provider appetite for risk?
A:There is strong demand to move to value, but discussions are more elongated due to economic concerns.
Q:Can you provide any color on the negative PYD taken for 2023?
A:The negative PYD was primarily from exited markets and a small amount related to 2024 dates of service.
Q:Can you provide any color on your second quarter guidance and expectations for 2Q?
A:We’re using a restated income statement on an incurred basis to develop our seasonality, and we expect a normal progression with higher profitability in earlier quarters.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the specific impact of the final rate notice on free cash flow and how much of the improvement can be attributed to it. They also did not provide clarity on the potential membership reduction into '26 if they cannot carve out Part D.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
EMRs
PCPs
President Investor
Ryan
Senior Vice
Vice President
administration official
advancement technology
capability
care delivery
comment administration
contracting
cost discipline
discipline foundation
disease progression
documentation
efficiency
example
exposure
focus
geography
heart failure
hospital
insight
investment technology
market dynamic
market trend
notice CMS
pathway
patient program
payer
quality outcome
topic
trend term
value care
variability
AGL Transcript
agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript
Unknown5-6
The company's earnings call presents a mix of positive and cautious elements. While there is optimism in revenue expectations and strategic initiatives, uncertainties in payer incentives and lack of clarity on AI risk adjustments temper enthusiasm. The market cap suggests moderate volatility, aligning with a neutral sentiment as the company navigates both growth opportunities and operational challenges.
agilon health, inc. (AGL) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-10
agilon health, inc. (AGL) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary presents mixed signals: while there are improvements in cash position and some positive financial metrics, the overall financial performance remains negative with significant losses and cost trends. The Q&A section highlights concerns about cost trends and unclear management responses, which could weigh on investor sentiment. The company's strategic focus on cost reduction and improved payer contracts is promising, but the lack of clear guidance on certain issues tempers optimism. Considering the company's market cap, the stock price is likely to remain relatively stable, resulting in a neutral sentiment.
agilon health, inc. (AGL) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed picture. While there are strategic plans for 2026, current issues like the negative impact of ACO REACH program changes and unclear management responses create uncertainty. The Q&A section highlights concerns about profitability and contract renewals, but also notes potential improvements in 2026. The market cap suggests moderate volatility, leading to a neutral sentiment as the stock may not significantly move in either direction over the next two weeks.
AGL Slides
AGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
